Using patient derived organoids (73), our findings may allow the assessment of epithelial phagocytic capabilities under defined genetic (e.g. ATG16L1 variants) and experimental inflammatory conditions and evaluate their contribution to homeostasis or if perturbed, to the pathogenesis of IBD. The gene discussed is ATG16L1; the disease is inflammatory bowel disease.